Affymetrix and bioMérieux Expand Collaboration . . .
Affymetrix and bioMérieux this week announced an expansion of a collaboration between the companies that the companies say will produce its first product offering during the fourth quarter.
The announcement follows comments made by Sue Siegal, Affymetrix’s president, during a presentation at the UBS Life Sciences Conference in New York last month (see BAN, 10/1/20), indicating that the company, the leader in the market for gene-expression profiling on microarrays, was expanding its market thrust to include applications such as paternity testing, feed testing and animal diagnostics, and crop testing.
This agreement, Affymetrix said, will allow the companies to enable the development of a broad spectrum of tests in infectious disease and industrial testing based on Affymetrix technology.
Affymetrix will receive upfront and milestone payments, and receive royalties for all collaborative products that are developed and commercialized by bioMérieux, the company said.
Affymetrix and bioMérieux have a relationship that dates as far back as 1996 when the companies issued a statement to announce a collaboration to develop “DNA probe arrays” that “will be the basis of diagnostic kits for bacterial identification and antibiotic resistance analysis.”
This week’s announcement says that bioMérieux will have non-exclusive access to Affymetrix technology for the determination of virulence factors, bacterial strain typing, and sepis diagnosis, including host pathogens’ response to infections. Further, bioMérieux has added rights in fields outside bacteriology to develop new assays for hepatitis B virus, and respiratory and central nervous system infectious panels.
BioMérieux will launch the product under the FoodExpert-ID brand and will market it with new instruments and software it has developed, Affymetrix said in its statement.
“The collaboration with Affymetrix is highly important in this field and demonstrates our determination to remain a major player within in vitro diagnostics and especially in molecular biology,” said Christophe Mérieux, vice president and director of medical affairs and research for bioMérieux. “Access to Affymetrix’s Genechip platform will allow us to introduce novel diagnostic tests into clinical routine while benefiting from Affymetrix’s groundbreaking technology and industrial-scale manufacturing facilities.”
. . . Spectral Genomics Licenses Affymetrix Patents for DNA Arrays
Spectral Genomics of Houston this week announced that it has licensed Affymetrix patents to manufacture and sell spotted DNA arrays for use in the research market.
“This license provides additional intellectual propperty enhancing Spectral’s proprietary position in BAC clone whole genome arrays for research in cytogenetics and molecular biology,” the company said in a statement. It did not disclose which patents it has licensed or provide details of the financial agreement.
Spectral Genomics develops and manufactures BAC clone arrays with 3,000 to 6,000 spots that cover the entire genome representing all the chromosomes at 10 times higher resolution than with traditional cytogenetic techniques. These arrays are used in research in pre-natal and post-natal genetic defects and in cancer research.
Affymetrix to Launch Advertising Campaign
The public relations firm Ruder Finn of New York last week announced the launch of a new advertising campaign for Affymetrix that will hinge on the number “1.” The Ruder Finn/Creative unit said the advertisements will run in scientific journals and genetic and drug-discovery publications. Ruder Finn/Creative has been Affymetrix’s ad agency since 2001 and handles media placements for Affymetrix.
Illumina Posts $8.2M Q3 Revenue Growth Atop Falling R&D Spend, Narrows Net Loss
Illumina last week reported an increase in third-quarter revenues atop fallen R&D expenditures and narrowed net loss.
Total revenue for the period ended Sept. 28 increased to $8.2 million from $3 million one year ago, the company said. Product sales, which increased to $6.5 million in the current third quarter from $1.3 million in the year-ago period, made up the brunt of total revenues. Receipts from services in the quarter remained relatively flat at around $1 million.
R&D spending in the quarter fell to $5.1 million from $6.4 million in the third quarter 2002.
Consequently, net loss narrowed to $5.5 million, or $.17 per share, from $7.6 million, or $.24 per share, year over year, Illumina said.
The company said it had around $51.2 million in cash and investments as of Sept. 28.